News Releases & Research Results Investigator-initiated clinical trial of cardiomyocyte sheets generated from iPS cells -Treatment of severe cardiomyopathy -

The results of collaborative R&D conducted by Professor Yoshiki Sawa of the Cardiovascular Surgery, Osaka University Graduate School of Medicine, and others.

• Highly safe cardiomyocytes that can be transplanted into humans were successfully produced in a large amount from iPS cells and formed into sheets.
• In 2019, a protocol for an investigator-initiated clinical trial to the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. In January 2020, an iPS cell-derived cardiomyocyte sheet was transplanted into a patient with severe cardiomyopathy as the first case.
• The results of R&D should lead to a novel therapy for severe heart failure, whose treatment is hindered by a serious shortage of donors.

This R&D project was conducted with the support of "Research Center Network for Realization of Regenerative Medicine" by the Japan Agency for Medical Research and Development (AMED).